Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive CNS noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive CNS noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens.
1. A food product effective for treating a patient suffering from a condition selected from the group consisting of metabolic syndrome, obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and procoagulative state, said food product comprising:
(a) nutrients that decrease overactive CNS noradrenergic tone; and
(b) nutrients that increase dopaminergic tone, wherein said nutrients that increase dopaminergic tone while maintaining said decreased overactive CNS noradrenergic tone comprises:
1) protein of about 24%±5% of total daily caloric intake;
2) monounsaturated fat of about 23%±5% of total daily caloric intake;
3) saturated fat of about 5%±5% of total daily caloric intake;
4) polyunsaturated fat of about 3%±5% of total daily caloric intake;
5) complex carbohydrate of about 45%±7% of total daily caloric intake;
6) total caloric set at 0-25% less than said patient's daily energy expenditure; and
7) L-DOPA in an amount sufficient to ingest about 20-400 mg of L-DOPA per day and wherein the nutrient that increases dopaminergic tone is L-DOPA, and said L-DOPA is present in an amount of between 20-400 mg.
2. The food product of claim 1 , wherein said nutrients that decrease overactive CNS noradrenergic tone comprise:
1) protein of about 25%±5% of total daily caloric intake;
2) monounsaturated fat of about 25%±5% of total daily caloric intake;
3) saturated fat of about 5%±5% of total daily caloric intake;
4) polyunsaturated fat of about 3%±5% of total daily caloric intake;
5) complex carbohydrate of about 42%±7% of total daily caloric intake; and
6) total calories of 15-25% less than the said patient's daily energy expenditure.
3. The food product of claim 1 , wherein polyunsaturated fat intake in each of nutrients (a) and (b) individually comprise a ratio of omega-3 to omega-6 polyunsaturated fatty acids from between about 0.25:1 to about 2:1.
4. The food product of claim 1 , wherein said food product comprises packaged foods, prepared meals, food bars, drinks, condiments, and combinations thereof.
5. The food product of claim 1 , wherein said polyunsaturated fat further comprises omega-3 and omega-6 polyunsaturated fatty acids, present in a ratio of omega-3 to omega-6 polyunsaturated fatty acids of from between about 0.25:1 to about 2:1.
6. The food product of claim 1 , wherein said food product provides between 75 and 85% of said patient's daily energy expenditure.
7. The food product of claim 1 wherein said food product provides between 75 and 100% of said patient's daily energy expenditure.
8. The food product of claim 1 wherein the nutrient that increases dopaminergic tone is L-DOPA.
9. The food product of claim 8 wherein the nutrient that decreases overactive CNS noradrenergic tone is pantethine.
10. A food product effective for treating a patient suffering from a condition selected from the group consisting of metabolic syndrome, obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and procoagulative state, said food product comprising:
1) protein of about 24%±5% of total daily caloric intake;
2) monounsaturated fat of about 23%±5% of total daily caloric intake;
3) saturated fat of about 5%±5% of total daily caloric intake;
4) polyunsaturated fat of about 3%±5% of total daily caloric intake;
5) complex carbohydrate of about 45%±7% of total daily caloric intake;
6) total caloric set at 0-25% less than said patient's daily energy expenditure; and
7) L-DOPA in an amount sufficient to ingest about 20-400 mg of L-DOPA per day.
11. A food product effective for treating a patient suffering from a condition selected from the group consisting of metabolic syndrome, obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and procoagulative state, said food product comprising:
(a) nutrients that decrease overactive CNS noradrenergic tone; and
(b) nutrients that increase dopaminergic tone and
wherein the nutrient that increases dopaminergic tone is L-DOPA and wherein the nutrient that decreases overactive CNS noradrenergic tone is pantethine.